← All trials
NCT05249816
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 18, 2022
- Primary completion
- Sep 30, 2022
- Completion date
- Sep 30, 2022
- First posted
- Feb 22, 2022
- Last posted
- Mar 25, 2022
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cogna Technology Solutions LLCLead sponsor
- NovavaxCollaborator
- Sheikh Khalifa Medical CityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.